5(24.0)) and Role Physical (31.6(29.9)) at EOT. MK-5172/MK-8742

with and without RBV had smaller mean declines, e.g. Vitality (6.4(23.5) and 1.9(19.8)) and Role Physical (9.1(24.6) and 5.5(22.4)). Minimal mean declines in summary scores, MCS and PCS, were observed for MK-5172/MK-8742 and PCS for MK-5172/ MK-8742/RBV (all p-values >0.1) [see Figure 1]; marginally significant declines in MCS for MK-5172/MK-8742/RBV (all p-values < 0.055); and significant declines in MCS and PCS (all p-values < 0.0003) for IFN group. CONCLUSION Subjects treated with MK-5172/MK-8742 had minimal impact to their HRQOL during therapy unlike selleck chemicals subjects who received an IFN or RBV-containing therapy. Disclosures: Jean Marie Arduino – Employment: Merck Sharp & Dohme, Corp. Chizoba Nwankwo – Employment: Merck Shazia Khawaja – Employment: Merck Isaias N. Gendrano – Employment: Merck Sharp & Dohme Corp; Stock Shareholder: Merck Sharp & Dohme Corp Peggy Hwang – Employment: Merck, Merck Michael Robertson – Employment: Merck; Stock Shareholder: Merck Niloufar Mobashery – Employment:

Merck; Stock Shareholder: Merck Barbara A. Haber – Employment: Merck The following people have nothing to disclose: Boan Zhang, Melissa Shaughnessy Background In the United States, an estimated 2.7 million persons are infected with Hepatitis C virus (HCV). In August 2012, CDC published guidelines recommending a one-time HCV antibody test of persons born from 1945 – 1965 (‘baby boomer cohort’). Methods Sharing of anonymized hepatitis C antibody test results performed Sclareol across the United States between March 2012 and March CHIR-99021 in vivo 2014 was facilitated by a private-public partnership between CDC and Quest Diagnostics. We analyzed 4,486,556 HCV antibody tests across two time periods: 6 months before (Mar-Aug 2012), and 19 months after (Sep 2013-Mar 2014) publication of the CDC recommendations. Data were also analyzed at the person level for 3 birth cohorts: 1) persons born since

1965; 2) persons born from 1945-1965 (‘baby boomer cohort’); and 3) persons born before 1945. Simple averages of the number of tests and positive results per month, stratified by time period and year of birth category were calculated. Results The average number of antibody tests per month performed increased by 5.7% from 171,617 before to 181,940 after guidance was released. The change varied by birth cohort with increases of 2.7% among those born since 1965, 15.4% among the baby boomer cohort, and a decline of 2.7% among those born before 1945. The average number of positive tests was similar before and after the publication of guidance (−0.5% overall) and varied by birth cohort (+6.8% among those born since 1965; −4.1% among the baby boomer cohort; and −12.8% among those born before 1945). Of the 3,067,909 unique persons with any antibody test, 31.9% were in the baby boomer cohort, which increased slightly before and after (from 29% before to 33% after guideline publication).